according to jhu
Johns Hopkins aims to develop personalized approach for cancer immunotherapy
Johns Hopkins aims to develop personalized approach for cancer immunotherapy
A new five-year collaboration between Johns Hopkins University and biopharmaceutical company Bristol-Myers Squibb aims to determine why some patients being treated for cancer respond to immunotherapy drugs called checkpoint blockers and some do not, and to develop more effective combination immunotherapies.Projects included in the collaboration will span laboratory research on patients' tumor samples and several early-stage clinical trials led by Johns Hopkins scientists at the Bloomberg-Kimmel Institute for Cancer Immunotherapy."We're at an inflection point of understanding the root causes of response and resistance to immunotherapy, and this collaboration will help propel the research needed to identify ways to expand immunotherapy effectiveness to more patients," says Drew Pardoll, director of the Bloomberg-Kimmel Institute.Under the agreement, scientists will focus on research aimed at revealing the ways cancer cells avoid or succumb to immune checkpoint-blocking drugs, which work by disrupting signaling systems used by cancers to avoid detection and destruction by immune cells.
additionally jpost
Tiny barcodes offer 'huge advance' in personalized cancer therapy
Tiny barcodes offer 'huge advance' in personalized cancer therapy
Share on Facebook Share on TwitterPersonalized cancer therapy just got a boost from a new diagnostic development at the Technion- Israel Institute of Technology in Haifa.The process involves the use of tiny quantities of different barcoded drugs which are checked a inside patient's tumor to determine effectiveness.The process, just published in Nature Communications, is similar to the process of allergy testing.Please share this article on Linkedin tooUsing synthetic DNA sequences as a form of extremely tiny barcodes, Prof. Avi Schroeder, of the university's Chemical Engineering Faculty and Integrated Cancer Center, and his colleagues developed a way to determine the suitability of any specific anticancer drug to any individual patient – before treatment even begins."The medical world is now moving toward personalized medicine, but treatments tailored only according to the patient's genetic characteristics don't always grant an accurate prediction of which medicine will be best for each patient," said Schroeder.
besides news-medical
Technion researchers develop new diagnostic technology for improving personalized cancer treatment
Technion researchers develop new diagnostic technology for improving personalized cancer treatment
Using synthetic DNA sequences as the tiniest of barcodes, Technion researchers have developed a new diagnostic technology for determining the suitability of specific anticancer drugs to a specific patient - before treatment even begins.The study, published today in Nature Communications, was led by Assistant Professor Avi Schroeder of the Technion Faculty of Chemical Engineering and the Technion Integrated Cancer Center."The medical world is now moving towards personalized medicine, but treatments tailored only according to the patient's genetic characteristics don't always grant an accurate prediction of which medicine will be best for each patient," explains Professor Schroeder."We, however, have developed a technology that complements this field."
No comments:
Post a Comment